Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Other Non-Current Assets: 2011-2025

Historic Other Non-Current Assets for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2025 value amounting to $160,000.

  • RedHill Biopharma's Other Non-Current Assets fell 78.35% to $160,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $160,000, marking a year-over-year decrease of 78.35%. This contributed to the annual value of $148,000 for FY2024, which is 0.68% up from last year.
  • Latest data reveals that RedHill Biopharma reported Other Non-Current Assets of $160,000 as of Q2 2025, which was up 8.11% from $148,000 recorded in Q4 2024.
  • RedHill Biopharma's 5-year Other Non-Current Assets high stood at $16.2 million for Q4 2021, and its period low was $15,000 during Q2 2022.
  • Its 3-year average for Other Non-Current Assets is $204,500, with a median of $147,500 in 2023.
  • Per our database at Business Quant, RedHill Biopharma's Other Non-Current Assets tumbled by 99.88% in 2022 and then surged by 4,005.56% in 2024.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Other Non-Current Assets stood at $16.2 million in 2021, then slumped by 99.07% to $150,000 in 2022, then dropped by 2.00% to $147,000 in 2023, then rose by 0.68% to $148,000 in 2024, then tumbled by 78.35% to $160,000 in 2025.
  • Its Other Non-Current Assets was $160,000 in Q2 2025, compared to $148,000 in Q4 2024 and $739,000 in Q2 2024.